College Station, Texas
October 9, 2002
ProdiGene, Inc. and
Sigma-Aldrich Fine Chemicals, a division of
Sigma-Aldrich Corporation
(NASDAQ:SIAL), announced today they have entered into an
agreement under which Sigma-Aldrich will manufacture and
distribute TrypZean(TM), an animal free recombinant trypsin
produced with ProdiGene's proprietary transgenic plant system.
Sigma-Aldrich, well known for its expertise in protein
production and processing, has made sizeable commitments to
transgenic plant processing capabilities, including the ability
to process proteins in an animal contamination free environment.
"Based on our development experience with ProdiGene this is a
very scalable process," remarks Dr. Cynthia Wooge,
Sigma-Aldrich's Manager, Process Development. "We expect the
full scale production process to be completed before year end."
This is the first product launch by any company of a large-scale
transgenic plant protein. Robert C. Dose, Vice President
Business Development observes, "We have been supplying sample
material to the pharmaceutical industry for over six months and
the response has been overwhelming, confirming our market
intelligence of a large demand for an animal free product such
as TrypZean(TM)."
About Trypsin
Trypsin is a naturally occurring protein that is produced in the
pancreas of all animals and breaks down protein chains as part
of the digestion process. It is a critical intermediary in the
bioprocessing of proteins, such as insulin, where it is used to
help cleave the protein into its active form. The market for
trypsin is rapidly growing as a result of the worldwide increase
in biological products and diseases that are treated with
biological proteins, such as diabetes. Trypsin is widely used in
cell culture applications for research and production of
recombinant proteins for clinical uses. Another application is
its use in the wound care markets as an oral treatment for
inflammatory edema, hematoma and pain associated with a wide
variety of internal and external wounds. The protein also has
uses in food processing and infant formulas.
Concerns surrounding the use of animal and human-derived
proteins in pharmaceutical manufacturing make ProdiGene's
expertise in the area of plant produced recombinant proteins an
attractive alternative. The technology offers an animal free
source of proteins as well as the capacity to produce large
volumes that can be easily scaled-up or down without risk of
significant capital investment. "We have performed numerous
studies and examined test data from customers' studies all with
very positive results," comments Dr. Zivko Nikolov, ProdiGene's
Vice President of BioProcess Development and Production, "All of
these studies have demonstrated TrypZean(TM) behaves equivalent
and in some applications superior to bovine or porcine trypsin."
About ProdiGene
ProdiGene, headquartered in College Station, Texas, is a private
biotechnology company that is developing and manufacturing
industrial and pharmaceutical proteins from the Company's
proprietary transgenic plant system. ProdiGene, as the first and
only company to produce and market recombinant proteins from
transgenic plants, is well positioned to capitalize on the
opportunities in the large and expanding recombinant protein
markets.
About Sigma-Aldrich
Sigma-Aldrich is a leading Life Science and High Technology
company. Its biochemical and organic chemical products and kits
are used in scientific and genomic research, biotechnology,
pharmaceutical development, the diagnosis of disease and
chemical manufacturing. It has customers in life science
companies, university and government institutions, hospitals and
in industry. Sigma-Aldrich operates in 34 countries and has over
6,000 employees providing excellent service worldwide.
Sigma-Aldrich is committed to the success of its customers,
employees and shareholders through leadership in Life Science,
High Technology and Service.
|